Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
Popovici-Muller, Janeta; Lemieux, René M; Artin, Erin; Saunders, Jeffrey O; Salituro, Francesco G; Travins, Jeremy; Cianchetta, Giovanni; Cai, Zhenwei; Zhou, Ding; Cui, Dawei; Chen, Ping; Straley, Kimberly; Tobin, Erica; Wang, Fang; David, Muriel D; Penard-Lacronique, Virginie; Quivoron, Cyril; Saada, Véronique; de Botton, Stéphane; Gross, Stefan; Dang, Lenny; Yang, Hua; Utley, Luke; Chen, Yue; Kim, Hyeryun; Jin, Shengfang; Gu, Zhiwei; Yao, Gui; Luo, Zhiyong; Lv, Xiaobing; Fang, Cheng; Yan, Liping; Olaharski, Andrew; Silverman, Lee; Biller, Scott; Su, Shin-San M; Yen, Katharine.
ACS Med Chem Lett
; 9(4): 300-305, 2018 Apr 12.
Artigo em Inglês | MEDLINE | ID: mdl-29670690
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future.
Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.
Diverse mechanisms of somatic structural variations in human cancer genomes.
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue.
TARGET-seq Takes Aim at Cancer Evolution through Multi-omics Single-Cell Genotyping and Transcriptomics.
Impacts of somatic mutations on gene expression: an association perspective.
A Landscape of Pharmacogenomic Interactions in Cancer.